Tag Archives: ALBO

Albireo Pharma (ALBO) Received its Third Buy in a Row

After Needham and Wedbush gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on Albireo Pharma today and set a price target

Cowen & Co. Maintains Their Buy Rating on Albireo Pharma (ALBO)

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Albireo Pharma (ALBO – Research Report), with a price target of $39.00. The company’s shares closed last Monday at $19.01, close to its 52-week

Albireo Pharma (ALBO) Gets a Buy Rating from Wedbush

Wedbush analyst Liana Moussatos maintained a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $69.00. The company’s shares closed last Monday at $19.18, close to its 52-week low of $16.13. According to

H.C. Wainwright Sticks to Their Buy Rating for Albireo Pharma Inc (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) on August 9 and set a price target of $62. The company’s shares closed on Friday at $22.86. According to TipRanks.com, Arce is

H.C. Wainwright Keeps Their Buy Rating on Albireo Pharma Inc (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc (ALBO – Research Report) today and set a price target of $62. The company’s shares closed yesterday at $31.88. According to TipRanks.com, Arce is a 4-star analyst

Analysts Offer Insights on Healthcare Companies: Albireo Pharma Inc (NASDAQ: ALBO), Adverum Biotechnologies (NASDAQ: ADVM) and Incyte Corp (NASDAQ: INCY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Albireo Pharma Inc (ALBO – Research Report), Adverum Biotechnologies (ADVM – Research Report) and Incyte Corp (INCY – Research Report) with bullish